Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 7;4(1):vdac112.
doi: 10.1093/noajnl/vdac112. eCollection 2022 Jan-Dec.

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Katharina Seystahl  1 , Felix Boakye Oppong  2 , Emilie Le Rhun  1 , Caroline Hertler  1 , Roger Stupp  3 , Burt Nabors  4 , Olivier Chinot  5 , Matthias Preusser  6 , Thierry Gorlia  2 , Michael Weller  1
Affiliations

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Katharina Seystahl et al. Neurooncol Adv. .

Abstract

Background: Levetiracetam (LEV) is one of the most frequently used antiepileptic drugs (AED) for brain tumor patients with seizures. We hypothesized that toxicity of LEV and temozolomide-based chemoradiotherapy may overlap.

Methods: Using a pooled cohort of patients with newly diagnosed glioblastoma included in clinical trials prior to chemoradiotherapy (CENTRIC, CORE, AVAglio) or prior to maintenance therapy (ACT-IV), we tested associations of hematologic toxicity, nausea or emesis, fatigue, and psychiatric adverse events during concomitant and maintenance treatment with the use of LEV alone or with other AED versus other AED alone or in combination versus no AED use at the start of chemoradiotherapy and of maintenance treatment.

Results: Of 1681 and 2020 patients who started concomitant chemoradiotherapy and maintenance temozolomide, respectively, 473 and 714 patients (28.1% and 35.3%) were treated with a LEV-containing regimen, 538 and 475 patients (32.0% and 23.5%) with other AED, and 670 and 831 patients (39.9% and 41.1%) had no AED. LEV was associated with higher risk of psychiatric adverse events during concomitant treatment in univariable and multivariable analyses (RR 1.86 and 1.88, P < .001) while there were no associations with hematologic toxicity, nausea or emesis, or fatigue. LEV was associated with reduced risk of nausea or emesis during maintenance treatment in multivariable analysis (HR = 0.80, P = .017) while there were no associations with hematologic toxicity, fatigue, or psychiatric adverse events.

Conclusions: LEV is not associated with reduced tolerability of chemoradiotherapy in patients with glioblastoma regarding hematologic toxicity and fatigue. Antiemetic properties of LEV may be beneficial during maintenance temozolomide.

Keywords: epilepsy; levetiracetam; seizure; temozolomide; toxicity.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consolidated standards of reporting trials (CONSORT) diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Walbert T, Harrison RA, Schiff D, et al. . SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-oncology. 2021;23(11):1835–1844 - PMC - PubMed
    1. Maschio M, Beghi E, Casazza MML, et al. . Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. PLoS One. 2017; 12(7):e0180470. doi:10.1371/journal.pone.0180470. - DOI - PMC - PubMed
    1. Julie DAR, Ahmed Z, Karceski SC, et al. . An overview of anti-epileptic therapy management of patients with malignant tumors of the brain undergoing radiation therapy. Seizure. 2019; 70:30–37. - PubMed
    1. Roth P, Pace A, Le Rhun E, et al. . Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO clinical practice guidelines for prophylaxis, diagnosis, treatment and follow-up†. Ann Oncol. 2021; 32(2):171–182. - PubMed
    1. Lynch BA, Lambeng N, Nocka K, et al. . The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004; 101(26):9861–6 - PMC - PubMed

LinkOut - more resources